TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03500393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely Supervised Exercise (REM)
Description: REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised Exercise (UNSUP)
Description: The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
Study: NCT02234778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TGI SVF material via intramuscular injection
Description: Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
Study: NCT01823536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Description: Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Description: Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Description: Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Description: Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Study: NCT02336048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Premedication
Description: Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Premedication
Description: Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
Study: NCT03199742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized App Coaching
Description: All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized App Coaching
Description: All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized App Coaching
Description: All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
Study: NCT00430391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD Consent
Description: Participants are randomized to DVD enhanced consent that is either high risk or low risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD Consent
Description: Participants are randomized to DVD enhanced consent that is either high risk or low risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD Consent
Description: Participants are randomized to DVD enhanced consent that is either high risk or low risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD Consent
Description: Participants are randomized to DVD enhanced consent that is either high risk or low risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD Consent
Description: Participants are randomized to DVD enhanced consent that is either high risk or low risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Control
Description: Participants are assigned to the routine, standard consent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Control
Description: Participants are assigned to the routine, standard consent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Control
Description: Participants are assigned to the routine, standard consent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Control
Description: Participants are assigned to the routine, standard consent.
Study: NCT02915640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote technology
Description: Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
Study: NCT03572153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Hypnosis
Description: Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
Study: NCT02565693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT03572153

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered White Noise Hypnosis
Description: Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
Study: NCT04206670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System and Questionnaires
Description: Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Waiting Control In-Home Technology System and Questionnaires
Description: Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
Study: NCT02936011

Intervention type: DEVICE
Group type: OTHER
Intervention: CTO PCI using Absorb Bioresorbable Vascular Scaffolds
Description: CTO PCI
Study: NCT02831608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Study: NCT02517983

Intervention type: OTHER
Intervention: epidemiology
Description: Relative prevalence of different chronic respiratory disease phenotypes
Study: NCT02416401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study: NCT02439138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1101
Description: Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
Study: NCT02565693

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin

Intervention type: DRUG
Group type: OTHER
Intervention: Carbasalate calcium

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Study: NCT04659161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules twice a day (BID)
Study: NCT01926236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Symptom Control
Description: Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Symptom Control
Description: Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-folinic acid
Description: L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
Study: NCT02746744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion of Mabthera/Rituximab every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dimethyl fumarate
Description: Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride solution
Description: Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium Chloride solution
Description: Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
Study: NCT03168555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid
Description: 1250 mg CDCA is given with a study meal
Study: NCT01985919

Intervention type: OTHER
Intervention: Obtaining human tissue for basic research or biospecimen bank
Study: NCT02229253

Intervention type: DRUG
Intervention: degarelix
Study: NCT03797508

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasound
Description: To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
Study: NCT01053403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine or Placebo
Description: 1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
Study: NCT03498976

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulsed radiofrequency
Description: Echoguided technic

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulsed radiofrequency
Description: Echoguided technic
Study: NCT00704431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848 (darapladib)
Description: 160 mg darapladib
Study: NCT04373707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg
Study: NCT00820560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839
Description: INCB007839 100 or 200 mg/dose as IR capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839
Description: INCB007839 100 or 200 mg/dose as IR capsules
Study: NCT04373707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
Study: NCT02095990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroquinone
Study: NCT02565693

Intervention type: DRUG
Group type: OTHER
Intervention: Dipyridamole
Study: NCT02095990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02670850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Caregiver Intervention Program
Description: Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
Study: NCT02565693

Intervention type: OTHER
Group type: OTHER
Intervention: No antithrombotic treatment
Study: NCT01065285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evaluation of vaccines against flu
Description: evaluate efficacy and tolerance
Study: NCT00871936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090
Description: SLx-4090

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04260152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Fibro-Gide
Description: Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
Study: NCT02831608

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00871936

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Study: NCT04144049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT921
Description: Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Study: NCT04260152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft (CTG
Description: Surgical recession root coverage with coronally advanced flap in combination with CTG
Study: NCT02937883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowerment intervention
Description: Empowerment intervention for persons with young onset dementia
Study: NCT04504539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mOPV
Description: mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mOPV
Description: mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
Study: NCT00060008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gadopentetate dimeglumine
Study: NCT02400632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGIC-TOUCH Drug-eluting Balloon
Description: in-stent restenosis treated with drug eluting balloon
Study: NCT04504539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose IPV
Description: FIPV (full dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose IPV
Description: FIPV (full dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose IPV
Description: FIPV (full dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose IPV
Description: FIPV (full dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fractional IPV
Description: fIPV (fractional dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fractional IPV
Description: fIPV (fractional dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fractional IPV
Description: fIPV (fractional dose injectable polio vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fractional IPV
Description: fIPV (fractional dose injectable polio vaccine)
Study: NCT03977545

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Actigraphy
Description: Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Actigraphy
Description: Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Actigraphy
Description: Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Actigraphy
Description: Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
Study: NCT02492308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF-MSC induction
Description: Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab induction
Description: The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4